As DNMT inhibitors show efficacy in MDS/AML, given the increased global methylation we observed in the ASXL1 mutant KBM5 cells, we next treated the ASXL1 mutant and corrected cells with the DNMT inhibitor AZA. Here, DNMT1 is linked to myelodysplastic syndrome.